首页> 中文期刊> 《解放军医学杂志》 >CMH为KBv200耐药相关中性鞘糖脂

CMH为KBv200耐药相关中性鞘糖脂

         

摘要

In order to study the relationship between the expression of neutral glycosphingolipids(N-GSLs) and MDR, N-GSLs in MDR cell line KBv200 and its parental cell line KB were studied. The N-GSLs were extracted and purified from the KB and KBv200 cells according to the modified method of Hakomori, then analysed by High Performance Thin Layer Chromatography (HPTLC). The effects of PPMP on the expression of N-GSLs in KBv200 cell line were also studied by the above method, its reversion on the KBv200 cells to Vincristine (VCR) was examined by MTT method. The results showed that the levels of CMH and CDH in KBv200 cells were higher than in KB cells, CMH was much more markedly increased, PPMP could reverse MDR by inhibiting CMH synthesis. It suggested that CMH is MDR associated N-GSLs in KBv200 cell line, and inhibition of CMH expression in tumor cells maybe a new way to reverse MDR.%为了研究耐药细胞株KBv200中性鞘糖脂表达的规律,采用改良的Hakomori法提取、纯化了KB及其耐药细胞株KBv200的中性鞘糖脂,行高效薄层层析,分析其含量的异同;并以糖脂合成抑制剂PPMP抑制KBv200中性鞘糖脂的合成,观察了其对KBv200耐药性的逆转作用。结果发现,KBv200的CMH和CDH表达较KB强,尤以CMH为著,PPMP能抑制KBv200细胞CMH的合成,并能逆转KBv200对长春新碱(VCR)的耐药性。说明CMH为KBv200耐药相关中性鞘糖脂,抑制耐药细胞CMH的合成可能是逆转肿瘤多药耐药的一种新方法。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号